scholarly journals The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae

2004 ◽  
Vol 54 (1) ◽  
pp. 281-282 ◽  
Author(s):  
M. R. Hammerschlag
Keyword(s):  
Chlamydia Pneumoniae ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

scholarly journals In Vitro Activity of a New Ketolide Antibiotic, HMR 3647, against Chlamydia pneumoniae

1998 ◽  
Vol 42 (6) ◽  
pp. 1515-1516 ◽  
Author(s):  
Patricia M. Roblin ◽  
Margaret R. Hammerschlag
Keyword(s):  
Chlamydia Pneumoniae ◽  
Minimum Bactericidal Concentration ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity

ABSTRACT The in vitro activities of HMR 3647, roxithromycin, erythromycin, and azithromycin against 19 strains of Chlamydia pneumoniaewere tested. The MIC at which 90% of the isolates are inhibited and the minimum bactericidal concentration at which 90% of the isolates are killed of HMR 3647 were 0.25 μg/ml (range, 0.015 to 2 μg/ml). Nine recently obtained clinical isolates from children with pneumonia were more susceptible (MICs, 0.015 to 0.0625 μg/ml) than older strains that had been passaged more extensively.

scholarly journals In Vitro Activities of Gemifloxacin (SB 265805, LB20304) against Recent Clinical Isolates of Chlamydia pneumoniae

1999 ◽  
Vol 43 (11) ◽  
pp. 2806-2807 ◽  
Author(s):  
Patricia M. Roblin ◽  
Tamara Reznik ◽  
Andrei Kutlin ◽  
Margaret R. Hammerschlag
Keyword(s):  
Chlamydia Pneumoniae ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Minimal Bactericidal Concentration ◽  
In Vitro Activity

ABSTRACT We compared the in vitro activity of gemifloxacin, a new quinolone antibiotic, to the activities of levofloxacin, moxifloxacin, trovafloxacin, erythromycin, and doxycycline against 20 isolates ofChlamydia pneumoniae. Gemifloxacin was the most active quinolone tested, with a MIC at which 90% of the isolates are inhibited and a minimal bactericidal concentration at which 90% of strains tested are killed of 0.25 μg/ml, but this activity was less than those of doxycycline and erythromycin.

scholarly journals 1280. In-Vitro Activity of Cefiderocol, Imipenem/Relebactam, & Ceftazidime/Avibactam in Ceftolozane/Tazobactam Resistant Strains of Multidrug Resistant Pseudomonas aeruginosa

2020 ◽  
Vol 7 (Supplement_1) ◽  
pp. S655-S655
Author(s):  
Daniel Navas ◽  
Angela Charles ◽  
Amy Carr ◽  
Jose Alexander
Keyword(s):  
Multidrug Resistant ◽  
Resistance Mechanisms ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
Resistance Testing ◽  
Clinical Samples ◽  
In Vitro Activity ◽  
Carbapenemase Gene ◽  
Resistant Strains

Abstract Background The activity of imipenem/relebactam (I/R), ceftazidime/avibactam (CZA) and cefiderocol (FDC) were evaluated against clinical isolates of multidrug resistant (MDR) strains of P. aeruginosa which was resistant to ceftolozane/tazobactam (C/T). The recent increase of MDR P. aeruginosa strains isolated from clinical samples has prompted research and development of new antimicrobials that can withstand its multiple resistance mechanisms. C/T is an effective option for treatment of MDR P. aeruginosa in our facility with only 10% of resistance in MDR strains, but the emergence of resistance may occur due to the presence of a carbapenemase gene or an ampC mutation. Methods Antimicrobial susceptibility testing for C/T Etest® (bioMérieux, Inc.) were performed on all MDR strains initially screened by the VITEK2® (bioMérieux, Inc.). 10% (n=20) of all MDR isolates were resistant to C/T by the CLSI 2019 breakpoints. These resistant isolates were tested for presence of a carbapenemase gene using the GeneXpert CARBA-R (Cepheid®) PCR and against CZA Etest® (bioMérieux, Inc.) I/R gradient strips (Liofilchem®) and FDC broth microdilution (Thermo Scientific™ Sensititre™). Results A total of 20 clinical isolates of MDR P. aeruginosa resistant to C/T were tested following standardized CLSI protocols and techniques. All 20 isolates were screened for the presence of a carbapenemase gene (blaVIM, blaNDM, blaKPC, blaOXA-48, blaIMP). A blaVIM gene was detected in 6 (30%) out of 20 isolates. FDC demonstrated the greatest activity with 85% (n=17) of susceptible isolates (CLSI MIC <4µg/dL). CZA (CLSI MIC <8µg/dL) and I/R (FDA MIC <2µg/dL) showed 15% (n=3) and 10% (n=2) of susceptible isolates respectively. FDC was active against all 6 blaVIM isolates, where all 6 strains were resistant to CZA and I/R as expected. 3 isolates tested non-susceptible against FDC; additional characterization was not performed at this time. Conclusion Based on these results, FDC demonstrated the greatest in-vitro activity against C/T resistant strains of MDR P. aeruginosa. FDC also demonstrated activity against all 6 MDR P. aeruginosa carrying blaVIM gene. FDC is a strong option to consider on MDR P. aeruginosa strains based on a resistance testing algorithm and a cost/effective protocol. Disclosures All Authors: No reported disclosures

In vitro activity of olorofim against clinical isolates of the Fusarium oxysporum and Fusarium solani species complexes

Mycoses ◽  
2021 ◽  
Author(s):  
Hamid Badali ◽  
Connie Cañete‐Gibas ◽  
Hoja Patterson ◽  
Carmita Sanders ◽  
Barbara Mermella ◽  
...  
Keyword(s):  
Fusarium Oxysporum ◽  
Fusarium Solani ◽  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity ◽  
Species Complexes

scholarly journals In Vitro Activity of Posaconazole against Clinical Isolates of Dermatophytes

2001 ◽  
Vol 39 (11) ◽  
pp. 4208-4209 ◽  
Author(s):  
F. Barchiesi ◽  
D. Arzeni ◽  
V. Camiletti ◽  
O. Simonetti ◽  
A. Cellini ◽  
...  
Keyword(s):  
Vitro Activity ◽  
Clinical Isolates ◽  
In Vitro Activity
Sign in / Sign up

Export Citation Format

Share Document